A US federal judge has ruled that Novo did not prove Lilly’s obesity drug ad campaign, which included claims of superiority, caused meaningful harm to Novo’s sales, according to BioPharma Dive. The decision means Novo’s request to block the ads was denied.

This case matters for pharma brand leaders as it shows the limits of legal action over competitor advertising. Courts may demand clear evidence of commercial harm before restricting rival marketing. Companies should assess how they substantiate claims of injury in future disputes.

Ferring will acquire Gameto, an IVF technology startup, in a deal worth up to $1.4 billion, according to BioPharma Dive. The buyout gives Ferring access to a technology that could make the in vitro fertilisation process less complex and demanding for patients.

This deal is notable for its size and focus on innovation in a tightly regulated industry. Senior executives in pharma and biotech should watch how this acquisition may shift the competitive field in IVF and influence future technology investments.

A new analysis from the non-profit ICER found that net launch prices for new medicines spiked significantly between 2022 and 2025, with most prices well above its cost-effectiveness guidelines, according to BioPharma Dive.

This trend puts additional scrutiny on pharma pricing and could prompt stronger responses from payers or regulators. Senior leaders in pharma and healthcare should monitor how these findings may affect reimbursement, access, and pricing negotiations.